Nasdaq · Healthcare
Liquidia Corp (LQDA)
As-reported financials and recent SEC filings for Liquidia Corp, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$158.3M
Net income
$-68.9M
Net margin
-43.5%
Diluted EPS
$-0.80
ROE
-154.0%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $158.3M | $14.0M | $17.5M | $15.9M | $12.9M |
| Gross profit | — | $8.1M | $14.6M | $13.1M | $9.8M |
| Operating income | $-51.4M | $-121.3M | $-73.4M | $-38.8M | $-33.8M |
| Net income | $-68.9M | $-128.3M | $-78.5M | $-41.0M | $-34.6M |
| Diluted EPS | $-0.80 | $-1.63 | $-1.21 | $-0.67 | $-0.70 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-06
View on EDGAR →42026-06-24
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →Largest Healthcare peers
Go deeper on LQDA
Search Liquidia Corp’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.